April 18, 2021
Article
Although curing advanced RCC is an admirable goal, there are many treatment options available on the horizon that result in substantial improvements in long-term outcomes.
March 30, 2021
Article
Oncologists deciding what to do about coronavirus disease 2019 vaccines are not alone.
September 23, 2020
Article
Immune checkpoint inhibitors blocking CTLA-4 or PD-1/PD-L1 often provide durable antitumor benefits to certain patients who respond to them; however, the percentage of responders is low, around 15% to 25%.
July 15, 2020
Article
Agents developed to prevent myelosuppression are the latest chemoprotectants under investigation in the treatment of various solid tumor malignancies.